Web Exclusives

In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months. Read More ›

Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read More ›

BRAF/MEK-targeted therapy rechallenge in patients with BRAF-mutation–positive advanced melanoma whose disease progress on first-line BRAF-targeted therapy and second-line immunotherapy leads to responses in approximately one-fourth of patients. Read More ›

In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment. Read More ›

Nivolumab continues to be an effective adjuvant treatment for patients with resected high-risk melanoma at 4 years, with sustained recurrence-free and distant metastasis-free survival benefit compared with ipilimumab. Read More ›

Analysis of the randomized COMBI-AD trial at 5 years shows >50% relapse-free survival in patients with resected stage III BRAF V600-mutation–positive melanoma who received adjuvant treatment with the combination of dabrafenib plus trametinib. Read More ›

The latest analysis of the phase 3 EORTC 1325/KEYNOTE-054 clinical trial showed pembrolizumab to be superior to placebo after more than 3.5 years of follow-up on the end points of distant metastasis-free survival and relapse-free survival in patients with resected stage III melanoma. Read More ›

Thyroid cancer is the most common form of endocrine malignancy and its incidence is increasing. Thyroid cancers usually present as painless nodules found upon palpation, and nodules >1 cm should be evaluated as they have a higher potential for being clinically significant cancers. Read More ›

RET is a tyrosine kinase receptor that, when fused with a partner molecule, activates oncogenic activity. RET abnormalities are found in both papillary and medullary thyroid cancers and are promising targets for treatment. Read More ›

Medullary thyroid cancer (MTC) accounts for 5% of all thyroid cancers. The only curative treatment option for MTC is surgery, but understanding of the RET pathway and the development of therapies targeting this pathway may improve outcomes for these patients. Read More ›

Page 10 of 42


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: